强联智创 is described as China’s first high‑tech company addressing pain points in cerebrovascular disease treatment. Its product R&D has accumulated more than four years of development. The company focuses on intelligent diagnosis and treatment within the cerebrovascular disease vertical and is portrayed as a leading player in that niche in China. Recently it completed a near‑RMB‑100 million D round. The financing is presented as a strategic investment intended to support the company’s future development trajectory. No operating metrics or founding year are disclosed in the article. Founded in September 2016, Qianglian Zhichuang develops an integrated AI diagnostic and treatment platform for hemorrhagic and ischemic stroke. Its product suite covers automated screening, precise diagnosis, intelligent surgical planning, intraoperative assistance and postoperative follow-up. Two products have received NMPA registration, and its UKnow® intracranial aneurysm surgical planning software was approved via the NMPA innovation green channel in April and is expected to pursue a Class III AI-assisted therapeutic registration. The company’s U-Pixel™ stroke AI cloud platform already covers hundreds of hospitals and has served thousands of patients. It supplies the UGuard® ischemic stroke AI diagnostic system and has strategic partnerships with GE Healthcare on CT and DSA products, including a joint neuro-interventional AI angiography machine. Qianglian plans to expand partnerships and promote intelligent stroke centers to broaden access to AI-enabled stroke prevention and treatment. 强联智创 is a high‑tech company using AI and big data for precise diagnosis and treatment of cerebrovascular disease, with a platform that covers both hemorrhagic and ischemic stroke full-care workflows. Its U-Pixel stroke intelligent diagnosis and treatment platform outputs structured disease parameters, risk assessments, screening, automatic diagnosis, treatment decisions, surgical planning, intraoperative assistance, and follow-up. The platform can interconnect bidirectionally with medical imaging devices and has been deployed at top neurology centers including Xuanwu, Tiantan, Changhai, and Huashan. The company received a product registration certificate in late 2019 and has completed commercial pilot rollouts covering hundreds of hospitals. 强联智创 positions its offering around treatment‑side clinical decision support (not just imaging) and monetizes via per‑patient intelligent diagnostic service fees rather than traditional software sales. The company has also formed a strategic cooperation with GE Healthcare to jointly launch a neuro‑intervention AI angiography system (IGS6) to support commercialization and device integration.

Total raised

$14M

Funding rounds

3

Latest round

Series D

Latest activity

Dec 2023